Management Team

Karen Barker has more than 30 years of experience in the pharma, biotech, and CRO industries at companies including PRA, INC, and Omnicare. Karen has an extensive strategic, operational, and financial track record managing Clinical Operations, Project Management, and Study Start-Up within complex matrix environments throughout Europe and Asia-Pacific.

An exceptional people manager with a very loyal following, Karen can quickly and effectively build and maintain stable, high-performing teams, generating solid operational and financial performance. She has successfully managed numerous company integrations and mergers, ensuring project, departmental, company, and employee continuity and growth.

Karen is responsible for Premier Research’s business in Europe focusing on customer, community and employee engagement. She has a specific interest in oncology and is an active member of the PharmaTimes International Steering Committee and an oncology patient advocacy group.

LaRae Bennett joined Premier Research in 2017 as Senior Director, Data Analytics. She brings more than 25 years of experience, building and leading teams that enable and facilitate corporations to recognize the full potential of their enterprise data as an asset. Ms. Bennett’s career in information technology has focused on the areas of data warehousing, data modeling, data integrations, and data analytics. Her expertise spans across industries as she has worked at companies such as Research Triangle Institute, ABB, Duke University Health Technologies, PPD, and Oracle. Ms. Bennett has an extensive background in data and data strategies including social and economic, international development, hospital and health, manufacturing, consulting services, and clinical research.

A visionary leader, she is able to bring together people with different backgrounds and skill levels and develop them into a highly functioning team with a focus on delivering an enterprise data strategy.

Today, Ms. Bennett leads a team that focuses on the areas of data integrations, data discovery, machine learning, and artificial intelligence, as well as exploring new capabilities and concepts to enable Premier Research to differentiate itself as a data and technology leader in support of clinical trial research. She thrives on the challenges that come with technology and the use of data that enables business transformation.

Nach Davé provides strategic and commercial input for Premier Research’s business activities. He brings more than 20 years of experience in the pharmaceutical and contract research industries to the position. He previously served as the Vice President of Regulatory at Premier and has been in leadership positions at both CROs and sponsor companies.

Mr. Davé previously led clinical and regulatory affairs at Maxx Orthopedics, a developer of orthopedic medical devices, and has held roles in clinical operations, business development, strategic consulting and medical affairs at companies such as Merck, Bristol-Myers Squibb, Aventis Pharmaceuticals and Mitsubishi Pharma America.

In his current role, Mr. Davé brings innovative solutions and grow Premier’s footprint in the areas of medical device development, real-world evidence, and government relations. He is keen to explore how innovative technology like AI, ML, and other developments can best support the growth of Premier’s business.

Mr. Davé holds a master’s degree in drug regulatory affairs from Long Island University and a bachelor’s degree in pharmacy from the University of Sciences-Philadelphia. He is a registered pharmacist.

Abie Ekangaki is responsible for providing strategic planning, coordination, knowledge, and expertise in biostatistics for projects and/or standalone consultative services for both internal and external clients. He supports the Business Development and Operations efforts for key customers to design and manage effective and efficient clinical trials/programs bringing specific statistical, drug development, and operational knowledge in the respective area of focus.

With more than 20 years of experience as a biostatistician, Dr. Ekangaki has worked as a research scientist with the World Health Organization in Switzerland, as a statistics lecturer at Macquarie University in Australia, and has held several technical and senior leadership positions in the pharmaceutical industry. Given his more than 17 years in the pharmaceutical industry, he is experienced at applying and advising on the statistical design and analysis of clinical trials in various therapeutic areas, from proof of concept and beyond.

Dr. Ekangaki received his PhD in statistics from the University of Southampton, UK.

Dr. Jasmina Jankicevic works with pharma, biotech, medical device, and cosmetic companies to drive clinical development, medical affairs and successful commercialization of innovative dermatologic and medical aesthetics solutions.

As a clinician, researcher, teacher and industry leader, Dr. Jankicevic has dedicated 20 years to innovation and optimization of therapeutic paradigms for more than 30 skin disorders including psoriasis, acne, rosacea, atopic dermatitis, skin and nail infections, wounds, hair loss, pigmentary disorders, autoimmune bullous dermatoses, genodermatoses, connective tissue diseases, photodamage, actinic keratosis and skin cancers.

She has successfully led clinical development programs and medical strategy in several companies including Premier Research, Allergan, Leo Pharma, and Murad.

Dr. Jankicevic is a trained dermatologist, and scientist, certified clinical research professional, trained journalist, published author and sought-after speaker. She holds Medical Degree, Master of Medical Sciences Degree and Board-Certification in Dermatology and Venereology from University of Belgrade, Serbia.

Michael King Jolly joined Premier Research in 2016 to oversee strategic drug development partnerships and to implement innovative technologies and alliances. He has more than 35 years of clinical research and drug development experience, having held senior positions in strategic partnering, medical and regulatory affairs, clinical operations, and R&D at some of the industry’s leading companies.

Dr. Jolly holds a Doctor of Pharmacy degree from the University of Texas-Austin and a bachelor’s degree in zoology from the University of North Carolina-Chapel Hill, and is a graduate of the Burroughs Wellcome Management Institute. He teaches at the School of Pharmacy at the University of North Carolina-Chapel Hill.

Janet Kube is responsible for ensuring operational excellence in collaboration with leadership and in support of the overall Medical Device & Diagnostics group, including collaborating with global resourcing on assignments as well as activity and metrics reporting, overseeing assigned project managers and directors, and empowering them to lead and direct global cross-functional teams and manage client expectations to achieve client satisfaction. In her role, Mrs. Kube also operates at a strategic support level for complex, critical, therapeutically aligned programs through key stakeholder engagement and cross-functional management.

With more than 20 years of experience in clinical drug development as well as medical device licensing exclusively in the CRO environment, she has taken on the responsibility of operational delivery on various trials and clients, with a focus on the cardiovascular as well as the orthopedic and pediatric fields. Before joining the drug development industry, Mrs. Kube worked as a Registered Pediatric Nurse in several departments of the pediatric hospital, including the neuro-pediatric and oncology ward.

Dr. April Marquick is a passionate cell and gene therapy expert with demonstrated ability to deliver regulatory impact throughout all stages of a clinical trial and translate these skills to post-marketing. She is proactive in nature with a proven record of developing and executing international and regional strategies and contingencies for cell and gene therapy clinical trials. With over eight years’ experience in both research and the regulatory industry, Dr. Marquick has worked with the global regulatory department at several companies.

She has acquired significant experience with managing complex clinical trials (phase 1-3), and post-marketing safety studies (phase 4, compassionate use programs) in the EU and UK, APAC, North and South America, and the Middle East. Dr. Marquick also has varied experience within the rare disease and pediatric field. She has led global early phase projects focused on an array of innovative therapies from adeno-associated viral vectors, lentiviral vectors, oncolytic viruses and adaptive T-cell approaches, in combination with medical device components for complex administration systems.

Dr. Marquick holds a Ph.D. in biomolecular engineering (drug discovery) from the University of Montpellier, France. She obtained her master’s degree in chemistry from Cardiff University, UK, and is fluent in English and French.

Scott Millard has spent his 25-plus year career focused in analgesia study delivery overseeing the strategy through to execution for analgesia programs. Mr. Millard’s leadership of the analgesia business and study execution expertise is the perfect pairing to provide sponsors with clean data that can be used confidently to support the marketing applications for their drugs in development.

Since joining Premier Research, Mr. Millard has served in a variety of roles with increasing scope and responsibility, including Senior Clinical Research Associate, Team Lead, Senior Manager, Project Manager, Senior Project Manager, Project Director, Senior Director, Executive Director, and Vice President. Mr. Millard served at a director level managing project managers and sponsor programs, specializing in analgesia and rheumatology.

Mr. Millard has a bachelor’s degree from the University of Texas and was certified as a Certified Clinical Research Associate in 1995 by the ACRP.

Kristi Miller leads a diverse, cross-functional team of regulatory affairs professionals at RPI, A Division of Premier Research, to develop and implement global regulatory strategy in conjunction with clients across all stages of development and therapeutic areas, including neurology, immunology, and oncology. Prior to joining RPI, Dr. Miller was the Director of Global Regulatory Affairs at Phamacyclics and previously spent 10 years at Genentech in regulatory affairs, providing regulatory leadership and executed strategy for products across development (pre-IND through post-marketing), including indications in asthma and ophthalmology.

Dr. Miller holds a bachelor’s degree in genetic engineering from Cedar Crest College and a Ph.D. in tumor cell biology from Northwestern University.

Andrea Ochoa is Vice President, Global Study Start-Up, at Premier Research. Ms. Ochoa has more than 19 years of clinical operations experience in a variety of roles, specializing in study start-up for the past 10 years. In her current role, she oversees Premier Research’s start-up function while providing expert advice and strategies to operationalize and navigate the complex global regulatory and start-up environment.

Prior to joining Premier Research, Ms. Ochoa held several positions of increasing responsibility at MDS Pharma Services and INC Research. She has a master’s degree in Cognitive-Behavioral Therapy from the Luria Institute in Madrid, Spain, and bachelor’s degrees in psychology (National Distance Education University, Madrid) and law (Complutense University of Madrid). Ms. Ochoa is certified as Lean Sigma Green Belt since 2009.

Angi Robinson has been conducting pediatric and rare disease studies at Premier Research for more than 15 years. She has provided oversight and full management support for over 30 rare disease studies, including multiple U.S. and global programs. She has also supported FDA pre-IND meetings, IND submissions, and NDA/BLA project directorship.

Ms. Robinson helped launch the first Best Pharmaceuticals for Children Act Coordinating Center, collaborating with leadership staff at NICHD. She served as the Project Manager for highly complex trials including pediatric sedation in the PICU and pediatric bipolar disorder. Ms. Robinson’s experience includes multiple study designs including PK/PD, adaptive design, and FDA fast track and breakthrough therapy designations. She has also directed several studies requiring the oversight of data safety monitoring boards and data monitoring committees.

Ms. Robinson earned a bachelor’s degree in cell and molecular biology from Tulane University in New Orleans, LA.

Victoria Watts, CIPT, is the Global Data Protection Officer at Premier Research.  She has compliance and legal risk management experience in a variety of industries, most recently within clinical research. Ms. Watts has extensive experience formulating, operationalizing, and implementing data protection compliance programs and is an expert in interpreting the General Data Protection Regulation (GDPR) as it relates to clinical research. Prior to joining Premier Research, she held positions of increasing responsibility in the fields of data protection and legal compliance.

Ms. Watts has a Master of Studies from the University of Oxford and both a Bachelor of Laws degree from the University of Law in the United Kingdom and a Bachelor of Arts degree from Royal Holloway, University of London. In the field of data protection, she is a Certified Information Privacy Technologist (CIPT) and holds other relevant certifications.  Ms. Watts is currently a member of the Training Advisory Board of the International Association of Privacy Professionals (IAPP) as well as a key contributor to the European CRO Federation (EUCROF) initiative to draft a GDPR Code of Conduct for the CRO industry.

Stacy Weil translates Premier Research’s strategy into actionable data initiatives that enable internal and external customers to achieve the highest level of performance and success. Prior to joining Premier Research, Ms. Weil was Vice President of Clinical Data Operations at PatientiP and held prior roles in leadership in the process improvement, data analytics, learning services, and project management groups at a large, global CRO.

Ms. Weil’s operations experience includes project management and therapeutic leadership in endocrine/metabolic, immunology, urology, women’s health, neuroscience, respiratory, and urology. Her trial oversight includes global and domestic trials and teams in the U.S., Canada, Latin America, Asia-Pacific, and the European Union. She holds a master’s degree in biomedical informatics from the University of Texas-Health and is currently working toward a doctoral degree in health informatics through the University of Texas-Health.